TABLE OF CONTENTS
1 INTRODUCTION 46
1.1 OBJECTIVES OF THE STUDY 46
1.2 MARKET DEFINITION 46
1.3 OVERVIEW OF THE EUROPE THYROID CANCER DIAGNOSTICS MARKET 46
1.4 LIMITATIONS 48
1.5 MARKETS COVERED 48
2 MARKET SEGMENTATION 51
2.1 MARKETS COVERED 51
2.2 GEOGRAPHICAL SCOPE 52
2.3 YEARS CONSIDERED FOR THE STUDY 53
2.4 CURRENCY AND PRICING 53
2.5 DBMR TRIPOD DATA VALIDATION MODEL 54
2.6 MULTIVARIATE MODELLING 57
2.7 PRODUCT TYPE LIFELINE CURVE 57
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 58
2.9 DBMR MARKET POSITION GRID 59
2.10 MARKET TESTING TYPE COVERAGE GRID 61
2.11 VENDOR SHARE ANALYSIS 62
2.12 SECONDARY SOURCES 63
2.13 ASSUMPTIONS 63
3 EXECUTIVE SUMMARY 64
4 PREMIUM INSIGHTS 67
4.1 PESTEL ANALYSIS 68
4.2 PORTERS FIVE FORCES 69
4.3 GROWTH STRATEGIES ADOPTED BY KEY MARKET PLAYERS 70
5 EPIDEMIOLOGY 71
6 REGULATORY FRAMEWORK OF THE EUROPE THYROID CANCER DIAGNOSTICS MARKET 72
6.1 REGULATORY SCENARIO IN THE U.S. 72
6.2 REGULATORY SCENARIO IN AUSTRALIA 73
6.3 REGULATORY SCENARIO IN JAPAN 73
6.4 REGULATORY SCENARIO IN CHINA 73
7 MARKET OVERVIEW 74
7.1 DRIVERS 76
7.1.1 RISING INCIDENCE AND PREVALENCE OF THYROID NODULES AND CANCER 76
7.1.2 RISING THYROID CANCER DIAGNOSTIC TESTS 76
7.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 77
7.1.4 RISING AWARENESS TOWARDS THYROID CANCER 77
7.2 RESTRAINTS 78
7.2.1 HIGH COST OF DIAGNOSTICS PROCEDURE 78
7.2.2 TISSUE DAMAGE DUE TO HIGH RADIATION EXPOSURE FROM IMAGING TESTS 79
7.3 OPPORTUNITIES 79
7.3.1 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 79
7.3.2 RISING OBESE POPULATION 80
7.4 CHALLENGES 80
7.4.1 STRINGENT REGULATORY FRAMEWORK FOR THE APPROVAL AND COMMERCIALIZATION OF CANCER DIAGNOSTIC PRODUCTS 80
7.4.2 LACK OF SKILLED AND CERTIFIED EXPERTISE 81
8 EUROPE THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 82
8.1 OVERVIEW 83
8.2 INSTRUMENTS 86
8.2.1 PATHOLOGY BASED INSTRUMENTS 87
8.2.1.1 PCR INSTRUMENTS 87
8.2.1.2 SLIDE STAINING SYSTEMS 87
8.2.1.3 TISSUE PROCESSING SYSTEMS 87
8.2.1.4 CELL PROCESSORS 88
8.2.1.5 OTHER PATHOLOGY-BASED INSTRUMENTS 88
8.2.2 IMAGING INSTRUMENTS 88
8.2.2.1 ULTRASOUND SYSTEMS 88
8.2.2.2 CT SYSTEMS 88
8.2.2.3 MRI SYSTEMS 88
8.2.2.4 OTHERS 88
8.2.3 BIOPSY INSTRUMENTS 89
8.2.3.1 NEEDLE BIOPSY 89
8.2.3.2 ENDOSCOPIC BIOPSY 89
8.2.3.3 CORE BIOPSY 89
8.2.3.4 OTHERS 89
8.2.4 OTHERS 89
8.3 CONSUMABLES & ACCESSORIES 90
8.3.1 KITS 91
8.3.1.1 PCR KITS 91
8.3.1.2 DNA POLYMERASE KITS 91
8.3.1.3 NUCLEIC ACID ISOLATION KITS 91
8.3.1.4 OTHERS 91
8.3.2 REAGENTS 92
8.3.2.1 ASSAYS 92
8.3.2.2 BUFFERS 92
8.3.2.3 PRIMERS 92
8.3.2.4 OTHERS 92
8.3.3 PROBES 92
8.3.4 OTHER CONSUMABLES 92
9 EUROPE THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE 93
9.1 OVERVIEW 94
9.2 IMAGING TEST 97
9.2.1 COMPUTED TOMOGRAPHY (CT) SCAN 98
9.2.2 MRI 98
9.2.3 POSITRON EMISSION TOMOGRAPHY (PET) SCAN 98
9.2.4 OTHERS 98
9.3 BLOOD TEST 99
9.3.1 BLOOD CHEMISTRY TESTS 100
9.3.2 COMPLETE BLOOD COUNT (CBC) 100
9.3.3 OTHERS 100
9.4 BIOPSY 100
9.4.1 NEEDLE BIOPSY 101
9.4.2 BRONCHOSCOPY BIOPSY 101
9.4.3 CORE BIOPSY 101
9.4.4 OTHERS 101
9.5 OTHERS 102
10 EUROPE THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 103
10.1 OVERVIEW 104
10.2 PAPILLARY CARCINOMA 107
10.3 FOLLICULAR CARCINOMA 108
10.4 OTHERS 109
11 EUROPE THYROID CANCER DIAGNOSTICS MARKET, BY STAGES 110
11.1 OVERVIEW 111
11.2 STAGE I 114
11.3 STAGE II 115
11.4 STAGE III 116
11.5 STAGE IV 117
12 EUROPE THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP 118
12.1 OVERVIEW 119
12.2 30-65 122
12.3 65 AND ABOVE 123
12.4 21-29 124
12.5 BELOW 21 125
13 EUROPE THYROID CANCER DIAGNOSTICS MARKET, BY END USER 126
13.1 OVERVIEW 127
13.2 HOSPITALS 130
13.3 ASSOCIATED LABS 131
13.4 INDEPENDENT DIAGNOSTIC LABORATORIES 131
13.5 DIAGNOSTIC IMAGING CENTERS 132
13.6 CANCER RESEARCH INSTITUTES 133
13.7 OTHERS 134
14 EUROPE THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 135
14.1 OVERVIEW 136
14.2 DIRECT TENDER 139
14.3 RETAIL SALES 140
15 EUROPE THYROID CANCER DIAGNOSTICS MARKET, BY REGION 141
15.1 EUROPE 142
15.1.1 GERMANY 152
15.1.2 U.K. 157
15.1.3 ITALY 162
15.1.4 FRANCE 167
15.1.5 SPAIN 172
15.1.6 RUSSIA 177
15.1.7 SWITZERLAND 182
15.1.8 TURKEY 187
15.1.9 BELGIUM 192
15.1.10 NETHERLANDS 197
15.1.11 REST OF EUROPE 202
16 EUROPE THYROID CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE 203
16.1 COMPANY SHARE ANALYSIS: EUROPE 203
17 SWOT ANALYSIS 204
18 COMPANY PROFILE 205
18.1 CANON INC. 205
18.1.1 COMPANY SNAPSHOT 205
18.1.2 COMPANY SHARE ANALYSIS 205
18.1.3 PRODUCT PORTFOLIO 206
18.1.4 RECENT DEVELOPMENTS 206
18.2 FUJIFILM CORPORATION 207
18.2.1 COMPANY SNAPSHOT 207
18.2.2 REVENUE ANALYSIS 207
18.2.3 COMPANY SHARE ANALYSIS 208
18.2.4 PRODUCT PORTFOLIO 208
18.2.5 RECENT DEVELOPMENT 208
18.3 F. HOFFMANN-LA ROCHE LTD 209
18.3.1 COMPANY SNAPSHOT 209
18.3.2 REVENUE ANALYSIS 209
18.3.3 COMPANY SHARE ANALYSIS 210
18.3.4 PRODUCT PORTFOLIO 210
18.3.5 RECENT DEVELOPMENT 210
18.4 QUEST DIAGNOSTICS INCORPORATED 211
18.4.1 COMPANY SNAPSHOT 211
18.4.2 REVENUE ANALYSIS 211
18.4.3 COMPANY SHARE ANALYSIS 212
18.4.4 PRODUCT PORTFOLIO 212
18.4.5 RECENT DEVELOPMENTS 212
18.5 ILLUMINA, INC. 214
18.5.1 COMPANY SNAPSHOT 214
18.5.2 REVENUE ANALYSIS 214
18.5.3 COMPANY SHARE ANALYSIS 215
18.5.4 PRODUCT PORTFOLIO 215
18.5.5 RECENT DEVELOPMENT 215
18.6 ABBOTT 216
18.6.1 COMPANY SNAPSHOT 216
18.6.2 REVENUE ANALYSIS 216
18.6.3 PRODUCT PORTFOLIO 217
18.6.4 RECENT DEVELOPMENT 217
18.7 BD 218
18.7.1 COMPANY SNAPSHOT 218
18.7.2 REVENUE ANALYSIS 218
18.7.3 PRODUCT PORTFOLIO 219
18.7.4 RECENT DEVELOPMENT 219
18.8 BEIJING O&D BIOTECH CO., LTD. 220
18.8.1 COMPANY SNAPSHOT 220
18.8.2 PRODUCT PORTFOLIO 220
18.8.3 RECENT DEVELOPMENTS 220
18.9 BIOMRIEUX SA 221
18.9.1 COMPANY SNAPSHOT 221
18.9.2 REVENUE ANALYSIS 221
18.9.3 PRODUCT PORTFOLIO 222
18.9.4 RECENT DEVELOPMENTS 222
18.10 DIASORIN S.P.A. 223
18.10.1 COMPANY SNAPSHOT 223
18.10.2 REVENUE ANALYSIS 223
18.10.3 PRODUCT PORTFOLIO 224
18.10.4 RECENT DEVELOPMENT 224
18.11 FONAR CORP. 225
18.11.1 COMPANY SNAPSHOT 225
18.11.2 REVENUE ANALYSIS 225
18.11.3 PRODUCT PORTFOLIO 226
18.11.4 RECENT DEVELOPMENTS 226
18.12 GENERAL ELECTRIC 227
18.12.1 COMPANY SNAPSHOT 227
18.12.2 REVENUE ANALYSIS 227
18.12.3 PRODUCT PORTFOLIO 228
18.12.4 RECENT DEVELOPMENTS 228
18.13 HOLOGIC INC. 229
18.13.1 COMPANY SNAPSHOT 229
18.13.2 REVENUE ANALYSIS 229
18.13.3 PRODUCT PORTFOLIO 230
18.13.4 RECENT DEVELOPMENT 230
18.14 KONINKLIJKE PHILIPS N.V. 231
18.14.1 COMPANY SNAPSHOT 231
18.14.2 REVENUE ANALYSIS 231
18.14.3 PRODUCT PORTFOLIO 232
18.14.4 RECENT DEVELOPMENT 232
18.15 MERCK KGAA. 233
18.15.1 COMPANY SNAPSHOT 233
18.15.2 REVENUE ANALYSIS 233
18.15.3 PRODUCT PORTFOLIO 234
18.15.4 RECENT DEVELOPMENT 234
18.16 MEDONICA CO. LTD 235
18.16.1 COMPANY SNAPSHOT 235
18.16.2 PRODUCT PORTFOLIO 235
18.16.3 RECENT DEVELOPMENT 235
18.17 MINFOUND MEDICAL SYSTEMS CO. LTD 236
18.17.1 COMPANY SNAPSHOT 236
18.17.2 PRODUCT PORTFOLIO 236
18.17.3 RECENT DEVELOPMENTS 237
18.18 MYRIAD GENETICS, INC. 238
18.18.1 COMPANY SNAPSHOT 238
18.18.2 REVENUE ANALYSIS 238
18.18.3 PRODUCT PORTFOLIO 239
18.18.4 RECENT DEVELOPMENTS 239

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.